Special Lecture
Trial design in psoriatic arthritis: what could be changed?
A. Kavanaugh1, T. Boyd2
- Division of Rheumatology, Allergy and Immunology, University of California, La Jolla, CA, USA. akavanaugh@ucsd.edu
- Division of Rheumatology, University of California, La Jolla, CA, USA.
CER8910
2015 Vol.33, N°4 ,Suppl.92
PI 0015, PF 0018
Special Lecture
Free to view
(click on article PDF icon to read the article)
PMID: 26458015 [PubMed]
Received: 28/08/2015
Accepted : 01/09/2015
In Press: 12/10/2015
Published: 14/10/2015
Abstract
A greater understanding of the underlying disease process, combined with the development of novel therapeutic agents, has led to innovative strategies in the treatment of psoriatic arthritis (PsA). This report addresses unmet needs in clinical trial design in PsA, and proposes some amendments that may yield data that can potentially improve patient outcomes in the management of PsA.
